Tailored nanoparticles for tumour therapy.
Gd doped iron-oxide nanoparticles were developed for use in tumour therapy via magnetic fluid hyperthermia (MFH). The effect of the Gd3+ dopant on the particle size and magnetic properties was investigated. The final particle composition varied from Gd0.01Fe2.99O4 to Gd0.04Fe2.96O4 as determined by Inductively coupled plasma atomic emission spectroscopy (ICP-AES). TEM image analysis showed the average magnetic core diameters to be 12 nm and 33 nm for the lowest and highest Gd levels respectively. The specific power adsorption rate (SAR) determined with a field strength of 246 Oe and 52 kHz had a maximum of 38Wg(-1) [Fe] for the Gd0.03Fe2.97O4 sample. This value is about 4 times higher than the reported SAR values for Fe3O4. The potential for in vivo tumour therapy was investigated using a mouse model. The mouse models treated with Gd0.02Fe2.98O4 displayed much slower tumour growth after the first treatment cycle, the tumour had increased its mass by 25% after 7 days post treatment compared to a 79% mass increase over the same period for those models treated with standard iron-oxide or saline solution. After a second treatment cycle the mouse treated with Gd0.02Fe2.98O4 showed complete tumour regression with no tumour found for at least 5 days post treatment.
ITRI, Biomedical Technology and Device Research Lab, Taiwan.
Pei-Shin
PS
Jiang
Philip
P
Drake
Hui-Ju
HJ
Cho
Chao-Hung
CH
Kao
Kun-Feng
KF
Lee
Chien-Hung
CH
Kuo
Xi-Zhang
XZ
Lin
Yuh-Jiuan
YJ
Lin
D000818:Animals; D045744:Cell Line, Tumor; D005290:Ferric Compounds / Q000627:therapeutic use*; D005682:Gadolinium / Q000627:therapeutic use*; D006979:Hyperthermia, Induced / Q000379:methods*; D051379:Mice; D053758:Nanoparticles / Q000627:therapeutic use*; D009374:Neoplasms, Experimental / Q000473:pathology* / Q000628:therapy*; D016896:Treatment Outcome
D005290:Ferric Compounds; C000499:ferric oxide; D005682:Gadolinium